Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;41(7):1629-1640.
doi: 10.1111/liv.14889. Epub 2021 Apr 22.

Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation

Quirino Lai  1 , Paolo Magistri  2 , Raffaella Lionetti  3 , Alfonso W Avolio  4 , Ilaria Lenci  5 , Valerio Giannelli  6 , Annarita Pecchi  7 , Flaminia Ferri  8 , Giuseppe Marrone  9 , Mario Angelico  5 , Martina Milana  5 , Vincenzo Schinniná  10 , Renata Menozzi  11 , Michele Di Martino  12 , Antonio Grieco  9 , Tommaso M Manzia  13 , Giuseppe Tisone  13 , Salvatore Agnes  4 , Massimo Rossi  1 , Fabrizio Di Benedetto  2 , Giuseppe M Ettorre  14 ; Sarco-Model Study Group
Collaborators, Affiliations

Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation

Quirino Lai et al. Liver Int. 2021 Jul.

Abstract

Background & aims: Sarcopenia in liver transplantation (LT) cirrhotic candidates has been connected with higher dropouts and graft losses after transplant. The study aims to create an 'urgency' model combining sarcopenia and Model for End-stage Liver Disease Sodium (MELDNa) to predict the risk of dropout and identify an appropriate threshold of post-LT futility.

Methods: A total of 1087 adult cirrhotic patients were listed for a first LT during January 2012 to December 2018. The study population was split into a training (n = 855) and a validation set (n = 232).

Results: Using a competing-risk analysis of cause-specific hazards, we created the Sarco-Model2 . According to the model, one extra point of MELDNa was added for each 0.5 cm2 /m2 reduction of total psoas area (TPA) < 6.0 cm2 /m2 . At external validation, the Sarco-Model2 showed the best diagnostic ability for predicting the risk of 3-month dropout in patients with MELDNa < 20 (area under the curve [AUC] = 0.93; P = .003). Using the net reclassification improvement, 14.3% of dropped-out patients were correctly reclassified using the Sarco-Model2 . As for the futility threshold, transplanted patients with TPA < 6.0 cm2 /m2 and MELDNa 35-40 (n = 16/833, 1.9%) had the worse results (6-month graft loss = 25.5%).

Conclusions: In sarcopenic patients with MELDNa < 20, the 'urgency' Sarco-Model2 should be used to prioritize the list, while MELDNa value should be preferred in patients with MELDNa ≥ 20. The Sarco-Model2 played a role in more than 30% of the cases in the investigated allocation scenario. In sarcopenic patients with a MELDNa value of 35-40, 'futile' transplantation should be considered.

Keywords: MELD; MELDNa; allocation; cirrhosis; dropout; futility; malnutrition; sarcopenia.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Freeman RB Jr, Wiesner RH, Harper A, et al.; UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8:851-858.
    1. Guy J, Somsouk M, Shiboski S, Kerlan R, Inadomi JM, Biggins SW. New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol. 2009;7:1236-1240.
    1. Cho HC, Jung HY, Sinn DH, et al. Mortality after surgery in patients with liver cirrhosis: comparison of Child-Turcotte-Pugh, MELD and MELDNa score. Eur J Gastroenterol Hepatol. 2011;23:51-59.
    1. Schaffer RL 3rd, Kulkarni S, Harper A, Millis JM, Cronin DC 2nd. The sickest first? Disparities with model for end-stage liver disease-based organ allocation: one region's experience. Liver Transpl. 2003;9:1211-1215.
    1. Tohidinezhad F, Eslami S, Abu-Hanna A, Aliakbarian M. Model for End-Stage Liver Disease and seven derivations to prioritize liver transplant candidates: which is the winner? Exp Clin Transplant. 2018;16:721-729.